Association of biomarkers of intestinal inflammation with indexes of ulcerative colitis activity

Authors

  • I.V. Psareva State Institution “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine”, Dnipro, Ukraine

DOI:

https://doi.org/10.22141/2308-2097.54.1.2020.199140

Keywords:

ulcerative colitis, diagnosis, index of ulcerative colitis activity, markers of inflammation in the blood, fecal markers of inflammation

Abstract

Background. The goal is to analyze the content of mar­kers of intestinal inflammation in the blood and feces of patients with ulcerative colitis (UC) in comparison with the known disease activity indices. Materials and methods. We examined 60 patients with a confirmed diagnosis of UC. The clinical activity of UC was evaluated using a clinical activity index of D. Rachmilewitz. Endoscopic activity of UC was determined by the Mayo index. The degree of UC activity was assessed by the combined Mayo index. Serum levels of α1-antitrypsin and C-reactive protein were determined. The content of myeloperoxidase, calprotectin and α1-antitrypsin in the feces was studied. Correlation analysis was carried out with the calculation of the Spearman’s rank correlation coefficient and its significance. Results. In patients with UC, a significant increase in the level of fecal myeloperoxidase was detected — by 4.5 times (p = 0.027) and α1-antitrypsin in the feces — by 3.6 times (p = 0.039) as the clinical activity of UC was increased. With a pronounced degree of endoscopic activity of UC, a significant increase in the level of markers of inflammation in the feces was noted: α1-antitrypsin — by 17.8 times (p = 0.037), calprotectin — by 1.7 times (p = 0.023), myeloperoxidase — by 4.3 times (p = 0.019). At the same time, the level of C-reactive protein and α1-antitrypsin in the blood did not have significant differences depending on the degree of activity of ulcerative colitis. Conclusions. In patients with UC, correlations were established between the level of myeloperoxidase and calprotectin in the feces and the index of endoscopic activity of UC (r = 0.63; p = 0.0008, and r = 0.53; p = 0.001, respectively), as well as between the level of fecal myeloperoxidase and the degree of disease activity according to the combined Mayo index (r = 0.68; p = 0.0001).

Downloads

Download data is not yet available.

References

Kawalec P, Stawowczyk E, Mossakowska M, Pilc A. Disease activity, quality of life, and indirect costs of ulcerative colitis in Poland. Prz Gastroenterol. 2017;12(1):60–65. doi:10.5114/pg.2017.66324.

Ananthakrishnan AN, Kaplan GG, Ng SC. Changing Global Epidemiology of Inflammatory Bowel Diseases-Sustaining Healthcare Delivery into the 21st Century. Clin Gastroenterol Hepatol. 2020;S1542-3565(20)30107-5. doi:10.1016/j.cgh.2020.01.028.

Yu YR, Rodriguez JR. Clinical presentation of Crohn's, ulcerative colitis, and indeterminate colitis: Symptoms, extraintestinal manifestations, and disease phenotypes. Semin Pediatr Surg. 2017;26(6):349–355. doi:10.1053/j.sempedsurg.2017.10.003.

Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13(2):144–164. doi:10.1093/ecco-jcc/jjy113.

Cao Q, Huang YH, Jiang M, Dai C. The prevalence and risk factors of psychological disorders, malnutrition and quality of life in IBD patients. Scand J Gastroenterol. 2019;54(12):1458–1466. doi:10.1080/00365521.2019.1697897.

Armuzzi A, Tarallo M, Lucas J, et al. The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe. BMC Gastroenterol. 2020;20(1):18. Published 2020 Jan 21. doi:10.1186/s12876-020-1164-0.

Pizarro G, Quera R, Figueroa C. Prognostic factors of ulcerative colitis at the moment of diagnosis. Rev Med Chil. 2017;145(10):1319–1329. doi:10.4067/S0034-98872017001001319.

Simian D, Fluxá D, Flores L, et al. Inflammatory bowel disease: A descriptive study of 716 local Chilean patients. World J Gastroenterol. 2016;22(22):5267–5275. doi:10.3748/wjg.v22.i22.5267.

Allez M, Lémann M. Role of endoscopy in predicting the disease course in inflammatory bowel disease. World J Gastroenterol. 2010;16(21):2626–2632. doi:10.3748/wjg.v16.i21.2626.

Boyko TI. Clinico-endoscopic and morphological parallels with non-specific ulcerative colitis. Bulletin of Biology and Medicine. 2013;1;68-73. (in Ukrainian).

Sturm A, Maaser C, Calabrese E, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohns Colitis. 2019;13(3):273–284. doi:10.1093/ecco-jcc/jjy114.

Travis SP, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012;61(4):535–542. doi:10.1136/gutjnl-2011-300486.

Mosli MH, Zou G, Garg SK, et al. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2015;110(6):802–820. doi:10.1038/ajg.2015.120.

Nikitin AV, Matyukhin AA, Mordasova VI, Latysheva MN. The value of calprotectin for assessing the activity of inflammation in ulcerative colitis. Clinical medicine. 2016;94(7):540-543. doi: 10.18821/0023-2149-2016-94-7-540-543. (in Russian).

Walsh AJ, Ghosh A, Brain AO, et al. Comparing disease activity indices in ulcerative colitis. J Crohns Colitis. 2014;8(4):318–325. doi:10.1016/j.crohns.2013.09.010. 

Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298(6666):82–86. doi:10.1136/bmj.298.6666.82.

Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625–1629. doi:10.1056/NEJM198712243172603.

Published

2021-09-06

How to Cite

Psareva, I. (2021). Association of biomarkers of intestinal inflammation with indexes of ulcerative colitis activity. GASTROENTEROLOGY, 54(1), 38–43. https://doi.org/10.22141/2308-2097.54.1.2020.199140

Issue

Section

Original Researches